Kingmed Diagnostics approves key proposals at 2024 AGM

Guangzhou Kingmed Diagnostics Group (SSE:603882) announced the successful passage of all proposed resolutions at its 2024 Annual General Meeting. The meeting, held at the company's headquarters in Guangzhou, saw the participation of shareholders representing 45.5912% of the company's total voting shares. Key approvals included the 2024 Board of Directors Work Report, the 2024 Supervisory Board Work Report, and the 2024 financial statements. Shareholders also approved the proposed profit distribution plan for 2024 and the reappointment of the auditing firm for 2025. Furthermore, the compensation packages for directors, senior management, and supervisors for both 2024 and 2025 were ratified. Certain related shareholders abstained from voting on the compensation resolutions. Legal counsel confirmed the legitimacy and validity of the meeting's procedures and resolutions.